* MediciNova Inc MNOV.OQ MNOV.O is expected to show no
change
in quarterly revenue when it reports results on February 14
(estimated).
*
* Refinitiv's mean analyst estimate for MediciNova Inc is
for a
loss of 8 cents per share.
* The one available analyst rating on the shares is "buy".
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for MediciNova
Inc is
$6, above its last closing price of $2.45.
This summary was machine generated February 10 at 22:30 GMT.
All figures in US dollars unless otherwise stated